Kura Oncology's $30M Milestone: Ziftomenib Trial Boosts Stock
Update: 2025-10-24
Description
Kura Oncology's stock surged after a $30 million milestone payment from Kyowa Kirin, triggered by the launch of Phase 3 trials for ziftomenib, their oral cancer treatment. These global trials target acute myeloid leukemia patients with specific genetic mutations, testing ziftomenib with both intensive and less-intensive chemotherapy. As the only menin inhibitor in late-stage trials for both chemo types, ziftomenib's progress is fueling investor optimism and confidence in Kura's precision medicine approach.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
